Ligand News and Research

RSS

$Phenoxodiol gets fast track status for its intended use in patients with hormone-refractory prostate cancer$

Phenoxodiol gets fast track status for its intended use in patients with hormone-refractory prostate cancer

Marshall Edwards today announced that the U.S. Food and Drug Administration (FDA) has granted the investigational anti-cancer drug, phenoxodiol, fast track status for its intended use in patients with hormone- refractory prostate cancer (HRPC).

26 Jan 2005

Ubiquitination protects against improper Notch signaling

The Notch pathway is an important molecular signaling mechanism whose existence has been known, or at least hinted at, for nearly a century since the identification of a mutant strain of Drosophila fruit flies with "notched" wings in Thomas Hunt Morgan's lab in 1910.

28 Dec 2004

Blocking a key molecule protects breast implants, permanent catheters, pacemakers and artificial joints from rejection and damage by the body

Blocking a key molecule protects breast implants, permanent catheters, pacemakers, artificial joints, glucose sensors for diabetics, and other biomaterials from rejection and damage by the body, according to a study published this month in The American Journal of Pathology.

20 Dec 2004

Wide angle X-ray scattering (WAXS) could help produce lead drugs for disease therapy

Structural changes in proteins can now be seen in increased detail, using a new application of an existing technique. The application, developed at the U.S. Department of Energy's Argonne National Laboratory, could help produce lead drugs for disease therapy.

8 Dec 2004

Fossil record of the human immune system reveals antibodies that block cancer metastasis

A team of researchers at The Scripps Research Institute has reconstructed the "fossil record" of the immune systems of a group of human cancer patients to investigate if they had ever produced antibodies against their disease.

4 Dec 2004

Cancer Research Technology grants AstraZeneca an exclusive license to a key patent

Cancer Research Technology Limited has announced that AstraZeneca has licensed exclusive worldwide rights to a patent family relating to a nuclear receptor/co-activator binding motif.

1 Dec 2004

Concord grapes increase good cholesterol

Drinking Concord grape juice significantly increased HDL--the good cholesterol--and significantly lowered two markers of inflammation in people with stable coronary artery disease, according to results of a study presented in the November issue of the journal Arteriosclerosis, Thrombosis and Vascular Biology.

16 Nov 2004

FDA fast tracks investigational anti-cancer drug, phenoxodiol

Marshall Edwards today announced that the U.S. Food and Drug Administration (FDA) has granted the investigational anti-cancer drug, phenoxodiol, Fast Track status for its intended use in patients with recurrent ovarian cancer.

4 Nov 2004

Stress response proteins offer a promising target for a novel drug guidance system

Their study, published in the September issue of the journal Cancer Cell, demonstrates how researchers can find protein tags that are unique to cancer cells and then tweak a drug delivery system to zero in on those tags and destroy the cells.

21 Sep 2004

New anti-inflammatory strategy for cancer therapy

A new strategy for cancer therapy, which converts the tumor-promoting effect of the immune system’s inflammatory response into a cancer-killing outcome, is suggested in research findings by investigators at the University of California, San Diego (UCSD) School of Medicine.

20 Sep 2004

Phase 1 clinical trial of new anticancer drug from Human Genome Sciences

Human Genome Sciences has begun dosing patients in a Phase 1 clinical trial of HGS-TR2J, a novel agonistic human monoclonal antibody to TRAIL Receptor 2, in patients with advanced solid malignancies.

25 Aug 2004

Self-recovery from Hep C infection linked to genes that suppress action of killer immune cells

In a study to be published in Science online Aug. 6, researchers at Johns Hopkins have found that genes involved in suppressing the body's defensive "killer" immune cells are a potential key factor in spontaneous recovery from hepatitis C.

5 Aug 2004

New glycan arrays discover autoimmunogenic activities of SARS-CoV

Researchers in New York City and Guangzhou, China applied the rapidly-developing carbohydrate microarray technology to study an inactivated SARS-coronavirus (SARS-CoV) vaccine and discovered autoimmunogenic activity of this newly identified human viral pathogen.

2 Aug 2004

Drug for multiple sclerosis prevented disease development when tested on animal models

Scientists from the Neurological Sciences Institute at Oregon Health & Science University have shown that an investigative drug for multiple sclerosis and related diseases prevented disease development when tested on animal models.

20 Jun 2004

Computational design used to engineer and construct a protein that could sense the nerve agent soman

Duke University Medical Center biochemists have used computational design to engineer and construct a protein that could sense the nerve agent soman. They said their achievement constitutes a proof-of principle that such engineered proteins can be made to detect nerve agents such as sarin and other toxic substances.

5 Jun 2004

Strategy to treat obesity through molecular liposuction

Researchers at The University of Texas M. D. Anderson Cancer Center have designed a strategy to treat obesity through “molecular liposuction.” The therapy destroys blood vessels supporting fat accumulation — causing the fat to rapidly break down and disappear.

10 May 2004

DakoCytomation has acquired exclusive worldwide rights to develop and commercialize pharmacogenomic diagnostic tests in the field of oncology

Human Genome Sciences, Inc. announced today a license agreement with DakoCytomation A/S (Glostrup, Denmark), under which DakoCytomation has acquired exclusive worldwide rights to develop and commercialize pharmacogenomic diagnostic tests in the field of oncology based on the TRAIL Receptor-1 (TRAIL-R1) and TRAIL Receptor-2 (TRAIL-R2) proteins.

31 Mar 2004